Raymond James & Associates’s Organon & Co OGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$1.95M Sell
102,157
-222,322
-69% -$4.61M ﹤0.01% 2242
2024
Q2
$6.72M Sell
324,479
-37,651
-10% -$748K ﹤0.01% 1385
2024
Q1
$6.81M Buy
362,130
+19,612
+6% +$337K ﹤0.01% 1374
2023
Q4
$4.94M Sell
342,518
-3,292
-1% -$44.8K ﹤0.01% 1542
2023
Q3
$6M Buy
345,810
+2,354
+0.7% +$49.1K 0.01% 1351
2023
Q2
$7.15M Buy
343,456
+23,349
+7% +$508K 0.01% 1259
2023
Q1
$7.53M Buy
320,107
+35,033
+12% +$941K 0.01% 1204
2022
Q4
$7.96M Sell
285,074
-13,498
-5% -$345K 0.01% 1129
2022
Q3
$6.99M Buy
298,572
+14,957
+5% +$452K 0.01% 1159
2022
Q2
$9.57M Buy
283,615
+5,660
+2% +$198K 0.01% 1006
2022
Q1
$9.71M Sell
277,955
-9,963
-3% -$341K 0.01% 1088
2021
Q4
$8.77M Buy
287,918
+26,750
+10% +$871K 0.01% 1179
2021
Q3
$8.56M Buy
261,168
+27,514
+12% +$880K 0.01% 1143
2021
Q2
$7.07M Buy
+233,654
New +$7.69M 0.01% 1273

Other funds holding OGN

Raymond James & Associates's OGN Position: Q3 2024 in Review

Raymond James & Associates reduced its Organon & Co (OGN) stake by 69% in Q3 2024, selling an estimated $4.61M and leaving 102,157 shares worth $1.95M. The position accounts for ﹤0.01% of the portfolio, ranked #2242.

Raymond James & Associates first reported a position in OGN in Q2 2021 and has held it in 14 quarters since. The position peaked at $9.71M in Q1 2022. 724 funds tracked by Wall St. Rank hold OGN as of Q3 2024.

  • Raymond James & Associates held 102,157 shares of Organon & Co worth $1.95M as of Q3 2024.
  • Raymond James & Associates sold 222,322 Organon & Co shares in Q3 2024, an estimated $4.61M.
  • Organon & Co made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2242 holding.
  • Raymond James & Associates first reported a position in Organon & Co in Q2 2021 and has held it in 14 quarters since.
  • Raymond James & Associates's Organon & Co position peaked at $9.71M in Q1 2022.
  • 724 funds tracked by Wall St. Rank held Organon & Co as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.